drug · small molecule
Anti-inflammatory
pre_registrationupdated 7mo agoby AimMax Therapeutics Inc🔗 ChEMBL
community read0 votes
🐶 often sniffed alongside
top 2Small molecule drug with a maximum clinical stage of Phase 3 (across all indications), with 11 investigational indications.
targets
Mitogen-activated protein kinase 11Mitogen-activated protein kinase 14
all catalysts(0)
nothing on the calendar yet
Trials studying Anti-inflammatory
- N/ALong Term Extension of Safety and Efficacy of Vagus Nerve Stimulator in Patients With Rheumatoid Arthritis (RA)
- phase1Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants
- phase2Autism Spectrum Disorder (ASD) Neurodevelopmental Disorder With Issues Social Behavior, Communication Issues, GI Dysfunction. Study is Multimodal Interventions Targeting These Pathways With cSVF, Stored MSCs, FMT and Diet Modification. Role of Autoimmunity, Gut-brain Issues, & Issues Examined.
- N/AEffect of a Combined Exercise and Anti-Inflammatory Nutritional Intervention in Frail Older Adults
- N/AAnti-Inflammatory Dietary Intervention for Rheumatoid Arthritis
News(10)
- As part of sales reorganization, Novo will cut 215 employees at US HQFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 1d ago
- With FDA nod, Regeneron brings an RNAi drug to autoimmune diseaseThe product of a collaboration with Alnylam, Livsayis is now Regeneron’s first marketed RNAi drug and will compete against established medicines from AstraZeneca and Argenx.biopharma_dive · 2d ago
- 5 acquisitions that forced Big Pharmas to co-parentAcquiring a biotech with an existing Big Pharma partner can impose financial and strategic constraints around data sharing and milestone and royalty payments—but it is “rarely a deal-breaker,” acco…biospace · 4d ago
- STAT+: Why the latest heart drug failures should make us all more skeptical of AI hypeOnce again, a hot new technology that was supposed to speed up drug research has fallen flat.stat · 13d ago
- Rezera revs up for $181M IPO to fund phase 3 trial of NLRP3 inhibitorRezera—the new name for NodThera—is aiming for a $181 million IPO to take its NLRP3 inhibitor into phase 3 trials for a cardiovascular disease.fiercebiotech · 16d ago
- Sanofi stops development of Nurix-partnered immune drugThe decision sparked a sell-off in Nurix shares as well as analyst debate about the prospects of drugs designed to degrade a tough-to-reach protein called STAT6.biopharma_dive · 17d ago
- AbbVie bets up to $1.47B for Nxera’s discarded IBD programAbbVie’s $100 million upfront cash payment will purchase global rights to Nxera’s deprioritized oral small molecule, which has already completed Phase 1 testing.biospace · 17d ago
- Sanofi’s axing of Nurix STAT6 program ‘not a target-related issue’Sanofi has discontinued an early-stage STAT6 degrader program licensed from Nurix Therapeutics, a decision analysts say is related to the asset itself or Sanofi’s strategic reprioritization rather…biospace · 17d ago
- AbbVie pens $1.4B deal for deprioritized IBD drug from NxeraAbbVie has added another angle to its relationship with Nxera, with the Big Pharma paying $100 million upfront for a phase 1 inflammatory bowel disease candidate.fiercebiotech · 17d ago
- Novartis faces $1.9B hit from Avidity fail but maintains confidence in $12B buyNovartis remains "very happy" with its $12 billion acquisition of Avidity Biosciences, despite a Phase 3 disappointment for the antibody-oligonucleotide conjugate del-desiran.biospace · 25d ago
Data sources
last refreshed 7m ago
Found something off?
comments(0)
5-min edit window · permanent after that